The Defense Post: Veterans Have More to Fear from Mild Traumatic Brain Injuries than Expected

Written By Lindsey McClelland

Dr. Michael Wyand, CEO of Oxeia Biopharmaceuticals, says the US must address its epidemic of mTBI for active military, veterans and those who will serve in the future.

Lindsey McClelland
Previous

News Release: KANSAS CITY AREA RESIDENTS ASKED TO PARTICIPATE IN PHASE 2 TRIAL OF OXE103
Next

Public Service Announcement: Phase 2 clinical trial for Oxeia’s concussion drug, OXE103